Merit Medical Systems, Inc. has completed the acquisition of Biolife Delaware, L.L.C., a Florida-based manufacturer of hemostatic products under the StatSeal and WoundSeal brands. The transaction, valued at approximately $120 million in cash and assumed liabilities, makes Biolife a wholly owned subsidiary of Merit. This move expands Merit’s post-procedure care offerings, particularly in bleeding control for percutaneous procedures. Biolife’s products, which help quickly seal wound sites and prevent complications, are expected to complement Merit's existing device portfolio used in cardiology, radiology, dialysis, and other clinical areas.
Fred P. Lampropoulos, Merit’s Chairman and Chief Executive Officer, highlighted, “The acquisition provides effective, differentiated, hemostatic solutions for all percutaneous devices with a broad range of clinical applications, including vascular closure and indwelling catheter bleeding complications. BioLife’s StatSeal and WoundSeal products address an estimated $350M global market opportunity, are clinically validated, and will enhance our ability to deliver comprehensive solutions to our customers. Moreover, with Merit’s resources and expertise, we believe we are well-positioned to further develop and expand the reach of these product lines, ultimately benefiting patients and healthcare providers globally.” Merit has updated its 2025 financial guidance to reflect the impact of the acquisition and reaffirmed previous projections. The acquisition supports Merit’s efforts to offer reliable tools that simplify post-procedure care and support clinical performance.
